Patients with high levels of circulating endothelial progenitor cells (EPC) following at least three months of anticoagulation for unprovoked venous thromboembolism (VTE) are at low risk of recurrent VTE—Results from the ExACT randomised controlled trial.

BACKGROUND: There is clinical need for a laboratory biomarker to identify patients who, following an unprovoked venous thrombosis (VTE), are at low VTE recurrence risk and can discontinue anticoagulation after a limited treatment duration (3–6 m). This secondary analysis of the ExACT study aimed to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EClinicalMedicine
Autors principals: Bradbury, Charlotte, Buckley, Tracey, Sun, Yong Zhong, Rose, Peter, Fitzmaurice, David
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6933150/
https://ncbi.nlm.nih.gov/pubmed/31891148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2019.11.011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars